Graft Versus Host Disease (GVHD)

Understanding Brain Fog, Chemo Brain, with Dr. Jorg Dietrich

Topic(s)

Living Well with Bone Marrow Failure

Managing Your Treatment

Presenter(s)

Jorg Dietrich, MD, PhD

In this webinar, Dr. Jorg Dietrich will discusses the diagnosis of brain fog/chemo brain and how patients can manage this symptom of disease and its treatments.

Advances in Transplant and GVHD with Dr. Corey Cutler

Thumbnail for video Watch Now

Topic(s)

Bone Marrow Transplant

Presenter(s)

Corey Cutler, MD, MPH, FRCPC

In this webinar, Dr. Corey Cutler discusses advances in transplant and treating GVHD, or Graft Versus Host Disease.

Treatment patterns of extracorporeal photopheresis in steroid-refractory graft versus host disease: A delphi study

Original Publication Date

July 22, 2025

Article Source

External Web Content

Steroid-refractory GvHD (SR-GvHD) following allogeneic transplant is a major clinical challenge and is associated with substantial mortality [1]. While the European Society for Bone and Marrow Transplantation (EBMT) recommends ruxolitinib for second-line treatment of GvHD [2]…

Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis After Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

Original Publication Date

June 17, 2025

Article Source

External Web Content

Abstract Purpose Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative treatment for advanced hematologic malignancies. HSCT using human leukocyte antigen (HLA)-mismatched donors is historically associated with inferior survival. Patients from underrepresented…

Low rates of chronic graft-versus-host disease with ruxolitinib maintenance following allogeneic HCT

Original Publication Date

May 15, 2025

Article Source

External Web Content

Key Points Prolonged ruxolitinib administration after allogeneic HCT is associated with low rates of clinically significant chronic GVHD. Abstract Despite recent advances in graft-versus-host disease (GVHD) prophylaxis, novel approaches to effective prevention of chronic GVHD…

Cyclosporin/Cyclophosphamide Is a Potential New SOC in GVHD Management

Original Publication Date

June 13, 2025

Article Source

External Web Content

Cyclophosphamide plus cyclosporin, a calcineurin inhibitor, significantly improved graft-vs-host disease (GVHD)–free relapse-free survival (RFS) compared with standard prophylaxis in patients with aggressive blood cancers who are undergoing stem cell transplant from a matched…

Pamela Stratton, MD FACOG

Institution

National Institute of Child Health and Human Development

Physician Status

accepting new patients

Primary Disease Area of Focus

Graft Versus Host Disease (GVHD)

Read more about Pamela Stratton, MD FACOG

Towards graft- versus-host disease-free alternative donor transplant platforms for patients with acquired aplastic anemia

Read more about Towards graft- versus-host disease-free alternative donor transplant platforms for patients with acquired aplastic anemia

Hematopoietic stem cell transplantation is a well-established treatment option for acquired aplastic anemia aplastic anemia: (ay-PLASS-tik uh-NEE_mee-uh) A rare and serious con

Jeanne M. Palmer, MD

Institution

Mayo Clinic, Phoenix, AZ

Physician Status

accepting new patients

Primary Disease Area of Focus

Graft Versus Host Disease (GVHD)

Myelodysplastic Syndromes (MDS)

Myeloproliferative Neoplasms (MPN)

Read more about Jeanne M. Palmer, MD

Leo Luznik, MD

Institution

Johns Hopkins University

Physician Status

accepting new patients

Primary Disease Area of Focus

Acute Myeloid Leukemia (AML)

Chronic Lymphocytic Leukemia (CLL)

Graft Versus Host Disease (GVHD)

Myelodysplastic Syndromes (MDS)

Read more about Leo Luznik, MD

Subscribe to Graft Versus Host Disease (GVHD)

AAMDSIF Awareness Week

Graft Versus Host Disease (GVHD)

Understanding Brain Fog, Chemo Brain, with Dr. Jorg Dietrich

Advances in Transplant and GVHD with Dr. Corey Cutler

Treatment patterns of extracorporeal photopheresis in steroid-refractory graft versus host disease: A delphi study

Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis After Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

Low rates of chronic graft-versus-host disease with ruxolitinib maintenance following allogeneic HCT

Cyclosporin/Cyclophosphamide Is a Potential New SOC in GVHD Management

Pamela Stratton, MD FACOG

Towards graft- versus-host disease-free alternative donor transplant platforms for patients with acquired aplastic anemia

Jeanne M. Palmer, MD

Leo Luznik, MD

Website Feedback